药品注册申请号:205596
申请类型:NDA (新药申请)
申请人:MERCK SHARP DOHME
申请人全名:MERCK SHARP AND DOHME CORP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 NOXAFIL POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Yes Yes AP 2014/03/13 2014/03/13 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/10/25 SUPPL-20(补充) Approval Labeling STANDARD ;Orphan
2022/01/20 SUPPL-14(补充) Approval Labeling STANDARD
2022/01/13 SUPPL-15(补充) Approval Labeling STANDARD
2021/06/17 SUPPL-13(补充) Approval Efficacy STANDARD ;Orphan
2021/05/31 SUPPL-12(补充) Approval Efficacy STANDARD
2020/09/16 SUPPL-10(补充) Approval Labeling STANDARD
2019/03/11 SUPPL-7(补充) Approval Labeling STANDARD
2019/02/21 SUPPL-8(补充) Approval Labeling STANDARD
2018/01/04 SUPPL-5(补充) Approval Labeling STANDARD
2016/09/09 SUPPL-4(补充) Approval Labeling STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
2015/11/13 SUPPL-3(补充) Approval Labeling STANDARD
2015/11/13 SUPPL-1(补充) Approval Labeling STANDARD
2014/03/13 ORIG-1(原始申请) Approval Type 3 - New Dosage Form PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 10117951 2029/03/13 Y 2018/12/06 PDF格式
8410077 2029/03/13 Y 2014/04/08 PDF格式
9023790 2031/07/04 Y U-3171 U-1698 U-3160 2015/05/29 PDF格式
9358297 2031/06/24 Y U-3171 U-3160 2016/06/23 PDF格式
9493582 2033/02/27 Y 2016/12/15 PDF格式
9750822 2029/03/13 Y 2017/11/28 PDF格式
001 5661151 2019/07/19 Y Y U-1454 PDF格式**本条是由Drugfuture回溯的历史信息**
9023790 2031/07/04 Y U-3160 U-3171 U-1698 PDF格式**本条是由Drugfuture回溯的历史信息**
9358297 2031/06/24 Y U-3160 U-3171 U-1454 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 NPP 2024/05/31
ODE-355 2028/06/17
I-881 2024/06/17
与本品治疗等效的药品
活性成分:POSACONAZOLE 剂型/给药途径:SOLUTION;INTRAVENOUS 规格:300MG/16.7ML (18MG/ML) 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
205596 001 NDA NOXAFIL POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Prescription Yes Yes AP 2014/03/13 MERCK SHARP DOHME
208768 001 ANDA POSACONAZOLE POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Prescription No No AP 2022/05/25 ENDO OPERATIONS
209983 001 ANDA POSACONAZOLE POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Prescription No No AP 2023/12/26 FRESENIUS KABI USA
211500 001 ANDA POSACONAZOLE POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Prescription No No AP 2023/12/26 MYLAN LABS LTD
214842 001 ANDA POSACONAZOLE POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Prescription No No AP 2023/12/26 EUGIA PHARMA
217553 001 ANDA POSACONAZOLE POSACONAZOLE SOLUTION;INTRAVENOUS 300MG/16.7ML (18MG/ML) Prescription No No AP 2023/12/26 GLAND PHARMA LTD
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database